» Articles » PMID: 35901239

Protease-activated Receptors in Health and Disease

Overview
Journal Physiol Rev
Specialty Physiology
Date 2022 Jul 28
PMID 35901239
Authors
Affiliations
Soon will be listed here.
Abstract

Proteases are signaling molecules that specifically control cellular functions by cleaving protease-activated receptors (PARs). The four known PARs are members of the large family of G protein-coupled receptors. These transmembrane receptors control most physiological and pathological processes and are the target of a large proportion of therapeutic drugs. Signaling proteases include enzymes from the circulation; from immune, inflammatory epithelial, and cancer cells; as well as from commensal and pathogenic bacteria. Advances in our understanding of the structure and function of PARs provide insights into how diverse proteases activate these receptors to regulate physiological and pathological processes in most tissues and organ systems. The realization that proteases and PARs are key mediators of disease, coupled with advances in understanding the atomic level structure of PARs and their mechanisms of signaling in subcellular microdomains, has spurred the development of antagonists, some of which have advanced to the clinic. Herein we review the discovery, structure, and function of this receptor system, highlight the contribution of PARs to homeostatic control, and discuss the potential of PAR antagonists for the treatment of major diseases.

Citing Articles

Neutrophil extracellular traps impede cancer metastatic seeding via protease-activated receptor 2-mediated downregulation of phagocytic checkpoint CD24.

Liu Y, Ma J, Ma Y, Wang B, Wang Y, Yuan J J Immunother Cancer. 2025; 13(2).

PMID: 40010762 PMC: 11865804. DOI: 10.1136/jitc-2024-010813.


A supramolecular FRET signal amplification nanoprobe for high contrast and synchronous imaging of cell surface receptor homodimers/heterodimers.

Wang Y, Yao F, Song L, Zhang M, Gong Z, Zhao Y Chem Sci. 2025; 16(11):4732-4740.

PMID: 39968283 PMC: 11831222. DOI: 10.1039/d4sc08004a.


Endothelial protease-activated receptor 4: impotent or important?.

Rajala R, Griffin C Front Cardiovasc Med. 2025; 12:1541879.

PMID: 39935714 PMC: 11810968. DOI: 10.3389/fcvm.2025.1541879.


Protease-activated receptors in vascular smooth muscle cells: a bridge between thrombo-inflammation and vascular remodelling.

Habibi A, Ruf W, Schurgers L Cell Commun Signal. 2025; 23(1):57.

PMID: 39891111 PMC: 11786455. DOI: 10.1186/s12964-025-02066-6.


Identification of a secreted protease from that induces intestinal pain and inflammation by cleavage of PAR.

Lakemeyer M, Latorre R, Blazkova K, Jensen D, Wood H, Shakil N bioRxiv. 2025; .

PMID: 39868234 PMC: 11761754. DOI: 10.1101/2025.01.15.633241.


References
1.
Oestreich J . SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis. Curr Opin Investig Drugs. 2009; 10(9):988-96. View

2.
Suidan H, Bouvier J, SCHAERER E, Stone S, Monard D, Tschopp J . Granzyme A released upon stimulation of cytotoxic T lymphocytes activates the thrombin receptor on neuronal cells and astrocytes. Proc Natl Acad Sci U S A. 1994; 91(17):8112-6. PMC: 44555. DOI: 10.1073/pnas.91.17.8112. View

3.
McMahon D, Workman A, Kohanski M, Carey R, Freund J, Hariri B . Protease-activated receptor 2 activates airway apical membrane chloride permeability and increases ciliary beating. FASEB J. 2017; 32(1):155-167. PMC: 5731123. DOI: 10.1096/fj.201700114RRR. View

4.
Cavanaugh K, Gurwitz D, Cunningham D, Bradshaw R . Reciprocal modulation of astrocyte stellation by thrombin and protease nexin-1. J Neurochem. 1990; 54(5):1735-43. DOI: 10.1111/j.1471-4159.1990.tb01228.x. View

5.
Kuriri F, Burchall G, Alanazi F, Antonipillai J, Dobie G, Beachemin N . Mice Lacking PECAM-1 and Ceacam1 Have Enhanced Platelet Secretion and Thrombus Growth: Novel Link with PAR4. Thromb Haemost. 2021; 122(6):961-973. DOI: 10.1055/a-1663-8108. View